⚡ Flash Summary
The Searle Company Limited (SEARL) held a corporate briefing session for FY2025. Key highlights include that the global pharmaceutical market is expected to reach USD 1.7 trillion in 2024-25, with a stable 5% CAGR projected to 2030. SEARL is the second largest pharmaceutical company in Pakistan in terms of units sold and revenue growing with a CAGR of 17% over the last 5 years. The company exports to 12 countries and is expanding.
📌 Key Takeaways
- 🌍 Global pharmaceutical market size is USD 1.7 trillion.
- 📈 Global pharmaceutical industry is expected to grow with a CAGR of 5-6%.
- 💊 Pakistan’s pharmaceutical industry size is USD 3.7 billion, approximately 0.2% of the global market.
- 🥇 SEARL is No.1 in therapeutic categories like cardiovascular, gynecology, and cough suppressants.
- 🥈 SEARL is the second-largest pharmaceutical company in Pakistan by units sold.
- 🏆 Six brands crossed PKR 1 billion in annual sales.
- 💰 Eight brands crossed PKR 500 million in annual sales.
- 🚀 Revenue has grown with a CAGR of 17% over the past 5 years.
- 🤝 TSCL takes pride in its achievements towards serving mankind.
- 🏅 Searle was ranked the most outstanding healthcare company in Pakistan by Asiamoney (2018 & 2021).
- 🌏 Searle has been part of Forbes Asia’s ‘Best Under A Billion’ rankings.
- 💼 Searle has a presence in 89% of all pharmaceutical categories.
- Export contributes around 11% of total revenue.
🎯 Investment Thesis
Based on the information, I issue a HOLD recommendation for Searle. Although the long-term growth prospects of the Pakistani pharmaceutical sector are appealing and Searle has a strong domestic footprint, the recent financial performance and associated risks merit caution. Investors should monitor SEARL’s financial performance closely.
Disclaimer: AI-generated analysis. Not financial advice.
